One was a case of breast cancer (described as moderately aggressive, BRCA negative, estrogen and progesterone receptor positive) in a 38-year-old female participant diagnosed 281 days after the second study injection and subsequently treated with outpatient lumpectomy, radiation and Tamoxifen. The gene discussed is PGR; the disease is breast cancer.